Elutia (NASDAQ:ELUT) Announces Earnings Results, Misses Estimates By $0.02 EPS

Elutia (NASDAQ:ELUT) issued its earnings results on Thursday. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.02), FiscalAI reports. The business had revenue of $2.43 million for the quarter, compared to the consensus estimate of $2.90 million.

Here are the key takeaways from Elutia’s conference call:

• Positive Sentiment: Elutia secured up to $26 million in additional non-equity capital, including a $15 million Avenue Capital credit facility and proceeds from the planned SimpliDerm sale. Management believes total projected cash sources of up to $54 million provide runway through the anticipated NXT-41x launch in 2028.
• Positive Sentiment: An independent blinded survey of 50 reconstructive surgeons found strong potential demand for NXT-41x: 96% expressed interest in using it, 100% would use it for high-risk patients, and 92% would champion it before their hospital’s value analysis committee.
• Positive Sentiment: Management reiterated that NXT-41 is expected to receive an FDA clearance decision in the fourth quarter of 2026, while NXT-41x remains targeted for clearance in the first half of 2027. Commercial manufacturing qualification is complete, with initial production capacity expected to support at least $300 million in annual revenue.
• Negative Sentiment: Second-quarter net sales declined to $2.4 million from $2.7 million, primarily because of a contract-manufacturer disruption affecting SimpliDerm. Continuing-operations net loss widened to $7.6 million from $7.1 million, and adjusted EBITDA loss increased to $4.6 million from $3.0 million as R&D spending rose.
• Neutral Sentiment: Elutia is narrowing its focus to NXT-41x by selling SimpliDerm and continuing a strategic process for its cardiovascular business. While this should reduce commercial expenses and concentrate resources, the transactions remain subject to closing and could temporarily leave the company without a commercial product before NXT-41x launches.

Elutia Price Performance

Elutia stock traded up $0.07 during trading hours on Friday, hitting $0.93. The company had a trading volume of 54,296 shares, compared to its average volume of 152,305. The firm has a market capitalization of $39.61 million, a P/E ratio of 1.08 and a beta of 0.87. The firm’s fifty day moving average is $0.94 and its 200-day moving average is $1.03. Elutia has a fifty-two week low of $0.50 and a fifty-two week high of $2.50.

Institutional Trading of Elutia

Several institutional investors have recently modified their holdings of ELUT. Virtu Financial LLC acquired a new position in Elutia during the third quarter worth $26,000. XTX Topco Ltd bought a new position in Elutia during the second quarter worth about $28,000. Jane Street Group LLC acquired a new position in shares of Elutia during the 1st quarter worth about $48,000. Citadel Advisors LLC bought a new position in shares of Elutia during the 3rd quarter valued at about $50,000. Finally, Renaissance Technologies LLC grew its position in shares of Elutia by 64.7% in the 4th quarter. Renaissance Technologies LLC now owns 102,116 shares of the company’s stock valued at $71,000 after purchasing an additional 40,123 shares during the period. Institutional investors and hedge funds own 74.03% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings cut shares of Elutia from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Thursday, July 23rd. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $6.00.

About Elutia

Elutia, Inc is a biopharmaceutical company focused on the development of novel nitric oxide therapies based on its proprietary polymeric nitric oxide platform. This technology is designed to enable sustained, controlled release of nitric oxide to targeted tissues, potentially overcoming the delivery challenges associated with gaseous nitric oxide and small‐molecule donors.

The company’s lead program is in preclinical development for pulmonary arterial hypertension, with additional research efforts aimed at other cardiovascular and respiratory conditions.